The combination of the third-generation EGFR-TKI nazartinib with the MEK inhibitor trametinib is under investigation in the phase I EATON trial (NCT03516214) both for first-line therapy of EGFR-mutated NSCLC and after the failure of previous EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.